Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2019 16h07 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 août 2019 16h08 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
28 août 2019 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
12 févr. 2018 15h17 HE
|
Federman & Sherwood
OKLAHOMA CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern...